NASDAQ:AKTX - Akari Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$4.10 +0.04 (+0.99 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$4.10
Today's Range$3.85 - $4.30
52-Week Range$1.56 - $9.20
Volume536,968 shs
Average Volume5.96 million shs
Market Capitalization$62.57 million
P/E Ratio-14.64
Dividend YieldN/A
Beta-3.96

Headlines

Akari Therapeutics (NASDAQ AKTX) News Headlines

Source:
DateHeadline
B. Riley Analysts Give Akari Therapeutics (AKTX) a $7.00 Price TargetB. Riley Analysts Give Akari Therapeutics (AKTX) a $7.00 Price Target
www.americanbankingnews.com - March 19 at 3:00 PM
Akari Therapeutics Plc Estimate MomentumAkari Therapeutics Plc Estimate Momentum
www.nasdaq.com - March 18 at 6:33 PM
What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
finance.yahoo.com - March 14 at 6:18 PM
Akari Therapeutics Plc - American Depositary SharesAkari Therapeutics Plc - American Depositary Shares
www.benzinga.com - March 14 at 9:52 AM
CLNE, ACB and CARA among premarket gainersCLNE, ACB and CARA among premarket gainers
seekingalpha.com - March 13 at 5:57 PM
Akari Therapeutics PLC ADRAkari Therapeutics PLC ADR
www.barrons.com - March 13 at 5:57 PM
Akari Therapeutics stock rockets on massive volume after successful pre-IND FDA meetingAkari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting
www.marketwatch.com - March 13 at 5:57 PM
Akari up 15% on FDA nod on trial design for CoversinAkari up 15% on FDA nod on trial design for Coversin
seekingalpha.com - March 13 at 5:57 PM
Why Thinly Traded Biotech Akari Is Jumping More Than 150%Why Thinly Traded Biotech Akari Is Jumping More Than 150%
www.benzinga.com - March 13 at 5:57 PM
Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics — New Research Emphasizes Economic Growth - GlobeNewswireFactors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics — New Research Emphasizes Economic Growth - GlobeNewswire
globenewswire.com - February 23 at 9:25 AM
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares UpAlexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
finance.yahoo.com - February 4 at 5:33 PM
Alexions Ultomiris Meets Primary Endpoint in aHUS Study - NasdaqAlexion's Ultomiris Meets Primary Endpoint in aHUS Study - Nasdaq
www.nasdaq.com - January 29 at 5:15 PM
Alexion's Ultomiris Meets Primary Endpoint in aHUS StudyAlexion's Ultomiris Meets Primary Endpoint in aHUS Study
finance.yahoo.com - January 29 at 5:15 PM
What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta ValueWhat You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value
finance.yahoo.com - December 26 at 4:42 PM
Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin - GlobeNewswireAkari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin - GlobeNewswire
globenewswire.com - December 2 at 9:17 AM
Akari Therapeutcis (AKTX) Highlights New Data on Differentiation of Drug Candidate CoversinAkari Therapeutcis (AKTX) Highlights New Data on Differentiation of Drug Candidate Coversin
www.streetinsider.com - December 1 at 9:40 AM
Akari announces new Coversin data, key readouts expected next quarterAkari announces new Coversin data, key readouts expected next quarter
seekingalpha.com - December 1 at 9:40 AM
Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate CoversinAkari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
finance.yahoo.com - November 30 at 4:39 PM
Akari Announces Third Quarter 2018 Financial Results and Business HighlightsAkari Announces Third Quarter 2018 Financial Results and Business Highlights
finance.yahoo.com - November 15 at 9:16 AM
Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development SummitAkari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit
finance.yahoo.com - November 15 at 9:16 AM
Form 6-K Akari Therapeutics Plc For: Oct 01Form 6-K Akari Therapeutics Plc For: Oct 01
www.streetinsider.com - October 3 at 4:19 PM
Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports ...Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports ...
globenewswire.com - September 30 at 4:52 PM
Akari Therapeutics Announces New Clinical Data in...Akari Therapeutics Announces New Clinical Data in...
www.benzinga.com - September 30 at 9:21 AM
Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akari’s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous LTB4 and C5 ActivityAkari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akari’s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous LTB4 and C5 Activity
finance.yahoo.com - September 30 at 9:21 AM
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLCAkari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC
globenewswire.com - September 28 at 9:19 AM
Akari Therapeutcis (AKTX) Reports Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLCAkari Therapeutcis (AKTX) Reports Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC
www.streetinsider.com - September 27 at 4:20 PM
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLCAkari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC
finance.yahoo.com - September 27 at 9:22 AM
Akari Announces Second Quarter 2018 Financial Results and Business HighlightsAkari Announces Second Quarter 2018 Financial Results and Business Highlights
finance.yahoo.com - September 27 at 9:22 AM
Akari Therapeutcis (AKTX) Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous PemphigoidAkari Therapeutcis (AKTX) Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid
www.streetinsider.com - September 13 at 9:29 AM
Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory PathwaysAkari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways
finance.yahoo.com - September 12 at 9:10 AM
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTXThe Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTX
finance.yahoo.com - August 20 at 9:40 AM
Akari Therapeutics net loss improves in Q1Akari Therapeutics net loss improves in Q1
seekingalpha.com - August 17 at 9:30 AM
Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical TrialsAkari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
finance.yahoo.com - August 17 at 9:30 AM
Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology AssociationAkari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
finance.yahoo.com - June 15 at 9:13 AM
Market Trends Toward New Normal in Independent Bank, First Busey, American Public Education, The First ...Market Trends Toward New Normal in Independent Bank, First Busey, American Public Education, The First ...
globenewswire.com - May 26 at 9:13 AM
How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead?How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead?
finance.yahoo.com - May 26 at 9:13 AM
Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now?Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now?
finance.yahoo.com - May 17 at 9:44 AM
BRIEF-David Horn Solomon Resigns As CEO Of Akari TherapeuticsBRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics
www.reuters.com - May 12 at 4:27 PM
Akari Therapeutcis (AKTX) CEO David Horn Solomon Resigns Following Investigation of Charges on Corporate Credit CardsAkari Therapeutcis (AKTX) CEO David Horn Solomon Resigns Following Investigation of Charges on Corporate Credit Cards
www.streetinsider.com - May 11 at 10:23 AM
Akari chief out on inappropriate expensesAkari chief out on inappropriate expenses
seekingalpha.com - May 11 at 10:23 AM
Edited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMTEdited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMT
finance.yahoo.com - March 22 at 9:44 AM
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical ... - GlobeNewswire (press release)Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical ... - GlobeNewswire (press release)
globenewswire.com - March 21 at 4:25 PM
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical ProgressAkari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress
finance.yahoo.com - March 21 at 10:38 AM
Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018
finance.yahoo.com - March 16 at 9:46 AM
Akari Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceAkari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
finance.yahoo.com - February 8 at 8:55 AM
Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical TrialsAkari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials
finance.yahoo.com - February 6 at 9:07 AM
Akari Therapeutics Strengthens Board with Two Senior Industry AppointmentsAkari Therapeutics Strengthens Board with Two Senior Industry Appointments
finance.yahoo.com - January 23 at 8:19 AM
Penumbra (PEN) Forms JV on Virtual Reality in Health Space ... - NasdaqPenumbra (PEN) Forms JV on Virtual Reality in Health Space ... - Nasdaq
www.nasdaq.com - January 6 at 5:43 AM
Anika Therapeutics Receives FDA Nod for Bone Repair Therapy - NasdaqAnika Therapeutics Receives FDA Nod for Bone Repair Therapy - Nasdaq
www.nasdaq.com - January 5 at 2:10 PM
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments - NasdaqThermo Fisher Buys Phenom-World, Aids Analytical Instruments - Nasdaq
www.nasdaq.com - January 5 at 2:10 PM
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel